Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer.
Immunoscore
MIBC
bladder cancer
cancer classification
chemotherapy
immunity
immuno-oncology
neoadjuvant
predictive
prognosis
surgery
tumor microenvironment
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
17 02 2021
17 02 2021
Historique:
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
3
8
2021
Statut:
epublish
Résumé
This review details the clinical utility of Immunoscore, measuring the immune response to cancer within the tumor microenvironment, in bladder cancer. Immunoscore was recently introduced into ESMO Clinical Practice Guidelines for gastrointestinal cancer and into the WHO classification of the Digestive System Tumors. In muscle-invasive bladder cancer (MIBC), the standard-of-care treatment is neo-adjuvant chemotherapy and cystectomy. However, only 50% of the patients are still alive at 5 years. The degree of histologic response positively correlated with Immunoscore and patients at lower risk of relapse or death were associated with a high-Immunoscore. Immunoscore is also predicting response to neoadjuvant chemotherapy-based treatment in several indications. This paves the way for the use of Immunoscore in clinical practice not only in gastrointestinal tumors but also in bladder cancer, and beyond.
Identifiants
pubmed: 33659099
doi: 10.1080/2162402X.2021.1888488
pii: 1888488
pmc: PMC7899086
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1888488Informations de copyright
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Clin Cancer Res. 2020 Oct 1;26(19):5198-5207
pubmed: 32669377
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
J Immunother Cancer. 2020 May;8(1):
pubmed: 32448799
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Oncoimmunology. 2012 Mar 1;1(2):179-188
pubmed: 22720239
Nature. 2019 Jul;571(7766):570-575
pubmed: 31243362
J Transl Med. 2016 Sep 20;14:273
pubmed: 27650038
Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3
pubmed: 30537506
J Leukoc Biol. 2008 Oct;84(4):981-7
pubmed: 18559950
Oncoimmunology. 2014 Jan 1;3(1):e27456
pubmed: 24800163
Semin Immunopathol. 2011 Jul;33(4):335-40
pubmed: 21461991
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Ann Oncol. 2020 Jul;31(7):921-929
pubmed: 32294529
Cancers (Basel). 2021 Jan 28;13(3):
pubmed: 33525361
J Clin Oncol. 2020 Nov 1;38(31):3638-3651
pubmed: 32897827
Oncoimmunology. 2014 Jan 1;3(1):e27884
pubmed: 24790795
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Int Immunol. 2016 Aug;28(8):373-82
pubmed: 27121213